Gender and Dopaminergic Medication Treatment in Early Parkinson Disease (P3.069)

CONCLUSIONS: Although we did not observe gender differences in the type and dose of dopaminergic treatment in LS-1 participants with early PD, further research is needed to evaluate gender influences on dopaminergic medication treatment in mid- and late-stage PD.Study Supported by: on behalf of the NET-PD LS1 investigators.Disclosure: Dr. Umeh has nothing to disclose. Dr. Pérez has nothing to disclose. Dr. Augustine has nothing to disclose. Dr. Dhall has received personal compensation for activities with UCP Pharma, Impax Pharmaceuticals, and Teva Neuroscience. Dr. Dewey has received personal compensation for activities with Bertek Pharmaceuticals, Inc., GlaxoSmithKline Inc., Boehringer Ingelheim Pharmaceuticals Inc., Teva Neuroscience, and Novartis. Dr. Dewey has received research support from the National Institutes of Health, Schwarz Biosciences, and Elan Corp. Dr. Mari has nothing to disclose. Dr. Simon has received personal compensation for activities with the Gerson Lehrman Group, Inflexxion, and Easton Associates as a consultant; and the National Institutes of Health, Michael J. Fox Foundation, and Harvard University. Dr. Simon holds stock options in Biogen Idec. Dr. Simon has received research support from GE Healthcare. Dr. Wills has nothing to disclose. Dr. Christine has received research support from Biotie and Genzyme Corporation. Dr. Schneider has nothing to disclose. Dr. Suchowersky has received personal compensation for activities with Merz Pharma, Aller...

Source: Neurology - April 9, 2014 Category: Neurology Authors: Umeh, C., Perez, A., Augustine, E., Dhall, R., Dewey, R., Mari, Z., Simon, D., Wills, A. M., Christine, C., Schneider, J., Suchowersky, O. Tags: Movement Disorders: Clinical Features of Parkinson ' s Disease Source Type: research